United Parcel Service Reports Mixed Financial Results
Shares of United Parcel Service (UPS) are down 4% after the logistics and delivery company reported mixed financial results for this year’s second quarter. The Atlanta, Georgia-based company, which is often seen as a bellwether for the U.S. economy, reported earnings per share of $1.55 U.S., which just missed analyst forecasts of $1.56 U.S. Sales in the period totaled $21.2 billion U.S. Wall Street had been looking for revenue of $20.9 billion U.S. Management blamed tariffs for a decline in shipping volumes. Specifically, UPS said that demand took a hit from new “de minimis” tariffs placed on low-value Chinese shipments. U.S. President Donald Trump’s administration has begun collecting tariffs on shipments under $800 U.S. from China that were previously duty-free. While those levies have been reduced to 54% from an initial level of 120% as part of a trade agreement, consumer demand has still taken a hit and shipments have declined. UPS did not update its full-year outlook for a second straight quarter, citing ongoing macroeconomic uncertainty. In its most recent forecast, issued in January of this year, UPS projected 2025 revenue of $89 billion U.S. The company also announced that it is maintaining its quarterly dividend at $1.64 U.S. per share and expects to spend $5.5 billion U.S. on dividend payments in 2025. Prior to today (July 29), the stock of UPS had declined 18% to trade at $101.58 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


